Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

mivavotinib (CB-659)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Calithera

Drug class:

FLT3 inhibitor, SYK inhibitor

Related drugs:

fostamatinib (2)

BAY-61-3606 (1)

piceatannol (0)

quizartinib (40)

ripretinib (11)

pexidartinib (6)

flonoltinib (0)

fostamatinib (2)

BAY-61-3606 (1)

piceatannol (0)

›

FLT3 mutation + DNMT3A mutation	Acute Myelogenous Leukemia	FLT3 mutation + DNMT3A mutation	Acute Myelogenous Leukemia	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D
FLT3 mutation + MLL mutation	Acute Myelogenous Leukemia	FLT3 mutation + MLL mutation	Acute Myelogenous Leukemia	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D
MLL rearrangement	Acute Lymphocytic Leukemia	MLL rearrangement	Acute Lymphocytic Leukemia	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D